Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy

International Journal of Infectious Diseases

Volumn 10, Issue 3, 2006, Pages 193-201

  Wittek, Riccardo ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Complications; Prophylaxis; Smallpox; Vaccine; VIG

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; LIVE VACCINE; NONSTEROID ANTIINFLAMMATORY AGENT; SMALLPOX VACCINE; STEROID; VACCINIA ANTIBODY;

ANAPHYLAXIS; ASEPTIC MENINGITIS; BLURRED VISION; BRAIN DISEASE; CORNEA DISEASE; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MANUFACTURE; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DYSPNEA; ECZEMA; ERADICATION THERAPY; ERYTHEMA MULTIFORME; EXANTHEMA SUBITUM; FETUS WASTAGE; FLUSHING; HEALTH CARE POLICY; HUMAN; HYPOTENSION; IMMUNE DEFICIENCY; INFECTION PREVENTION; INJECTION PAIN; INJECTION SITE INFECTION; INJECTION SITE REACTION; KERATITIS; KIDNEY DISEASE; LACRIMATION DISORDER; MALAISE; NAUSEA AND VOMITING; PAIN; PATIENT MONITORING; PERICARDITIS; POSTVACCINAL ENCEPHALITIS; PREGNANT WOMAN; PREMATURITY; REVIEW; RIGOR; RISK FACTOR; SKIN DEFECT; SMALLPOX; SMALLPOX VIRUS; STEVENS JOHNSON SYNDROME; SWEAT GLAND DISEASE; TACHYPNEA; THORAX PAIN; THOUGHT DISORDER; TREATMENT CONTRAINDICATION; URTICARIA; VACCINATION REACTION; VACCINIA; VISUAL IMPAIRMENT; WEAKNESS;

BIOTERRORISM; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS; PROGRAM DEVELOPMENT; SMALLPOX VACCINE; VACCINIA; VACCINIA VIRUS;

EID: 33646093454     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2005.12.001     Document Type: Review

References (47)

1. World Health Organization. The global eradication of smallpox: final report of the Global Commission for the Certification of Smallpox Eradication, Geneva, December 1979. World Health Organization 1980, 1-122.
2. Heymann D.L. Smallpox containment updated: considerations for the 21st century. Int J Infect Dis 8 Suppl. 2 (2004) S15-S20
3. O'Toole T., Mair M., and Inglesby T.V. Shining light on "Dark Winter". Clin Infect Dis 34 (2002) 972-983
4. Amorosa V.K., and Isaacs S.N. Separate worlds set to collide: smallpox, vaccinia virus vaccination, and human immunodeficiency virus and acquired immunodeficiency syndrome. Clin Infect Dis 37 (2003) 426-432
5. Ministry of Defence.1998. Available at: http://www.mod.uk/issues/gulfwar/info/medical/bwa/annexes/annexii.htm.
6. Poland G.A., Grabenstein J.D., and Neff J.M. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine 23 (2005) 2078-2081
7. Henderson D.A. Bioterrorism as a public health threat. Emerg Infect Dis 4 (1998) 488-492
8. LeDuc J.W., and Jarhling P.B. Strengthening national preparedness for smallpox: an update. Emerg Infect Dis 7 (2004) 155-157
9. Thorne C.D., Hirshon J.M., Himes C.D., and McDiarmid M.A. Emergency medicine tools to manage smallpox (vaccinia) vaccination complications: clinical practice guideline and policies and procedures. Ann Emerg Med 42 (2003) 665-680
10. Weaver JC. Smallpox vaccine: mandating risk to ward off an old enemy? American Health Consultants, ED Legal Letter, February 2003. Available at: http://www.ahcpub.com/smallpox_article1_body.htm.
11. Alibek K, Handleman S. Biohazard. New York: Random House, 1999.
12. Leiberman J. Statement. United States Senate Committee on the Judiciary. BioShield II: Responding to An Ever Changing Threat. October 6, 2004. Available at: http://www.senate.gov/comm/judiciary/general/print_member_statement.cfm?id=1327&wit_id=3929.
13. Henderson D.A., Inglesby T.V., Bartlett J.G., Ascher M.S., Eitzen E., Jahrling P.B., et al. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 281 (1999) 2127-2137
14. Tennyson H.C., and Mair E.A. Smallpox: what every otolaryngologist should know. Otolaryngol Head Neck Surg 130 (2004) 323-333
15. McKinney WP, Bia FJ, Stewart C, Bosker G. Bioterrorism: an update for clinicians, pharmacists and emergency management planners. Emergency Medicine Consensus Reports. Consensus Panel Statements for Outcome-Effective and Evidence-Based Patient Management, Number 1. American Health Consultants, 2001. Available at: http://antibiotic-consult-pda.com/articles/bioterror.htm.
16. Larkin M. Smallpox looms large - in life, and on the web. Lancet Infect Dis 3 (2003) 114-115
17. Ministry of Defence 2002. Available at: http://news.mod.uk/news/press/news_press_notice.asp?newsItem_id=2225.
18. Grabenstein J.D., and Winkenwerder Jr. W. US military smallpox vaccination program experience. J Am Med Assoc 289 (2003) 3278-3282
19. Kempe C.H., Bowles C., Meiklejohn G., Berge T.O., St Vincent L., Sundara Babu B.V., et al. The use of vaccinia hyperimmune gamma-globulin in the prophylaxis of smallpox. Bull World Health Organ 25 (1961) 41-48
20. Wharton M., Strikas R.A., Harpaz R., Rotz L.D., Schwartz B., Casey C.G., et al. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 52 RR-7 (2003) 1-16. http://www.cdc.gov/mmwr/preview/mmwrhtml/m2d226.htm Available at:
21. Halsell J.S., Riddle J.R., Atwood J.E., Gardner P., Shope R., Poland G.A., et al. Myopericarditis following smallpox vaccination among vaccinia-naïve US military personnel. J Am Med Assoc 289 (2003) 3283-3289
22. Maurer D.M., Harrington B., and Lane J.M. Smallpox vaccine: contraindications, administration, and adverse reactions. Am Fam Physician 68 (2003) 889-896
23. ® Package Insert. Wyeth, 2004. Available at: http://www.fda.gov/cber/label/smalwye110504LB.pdf.
24. ACAM2000 Cell-culture derived smallpox vaccine. Available at: http://www.acambis.com/default.asp?id=1218.
25. Cono J., Casey C.G., and Bell D.M. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm Rep 53 RR-4 (2003) 1-28
26. Scott D. FDA role in counterterrorism: use of vaccinia immune globulins to treat adverse events after smallpox vaccine. Advisory Committee on Blood Safety and Availability. DHHS (2002) 1-9
27. Lane J.M., Ruben F.L., Neff J.M., and Millar J.D. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis 122 (1970) 303-309
28. FDA. Product approval information. Vaccinia Immune Globulin Intravenous (Human), Cangene Corporation. May 3, 2005. Available at: http://www.fda.gov/cber/products/vigivcan050305.htm.
29. FDA. Product approval information. Vaccinia Immune Globulin Intravenous (Human), Dynport Vaccine Company. February 18, 2005. Available at: http://www.fda.gov/cber/products/vigivdyn021805.htm.
30. Department of Health. Guidelines for smallpox response and management in the post-eradication era [Version 2], December 2, 2002. Available at: http://www.dh.gov.uk/assetRoot/04/07/08/32/04070832.pdf.
31. Roth CE. WHO response to the threat of smallpox, and strategic vaccine reserves. In: Paul-Ehrlich-Institut, G7+ - Global Health Security Initiative (GHSI) Workshop. Best practices in vaccine production for smallpox and other potential pathogens. September 5-6, 2002. WHO 2003; 22-3. Available at: http://www.who.int/csr/disease/smallpox/en/bestpractices.pdf.
32. Hendriks J. Stockpiling of smallpox vaccines: the European Plan. In: Paul-Ehrlich-Institut. G7+ - Global Health Security Initiative (GHSI) Workshop. Best practices in vaccine production for smallpox and other potential pathogens. September 5-6, 2002. WHO, 2003; 22-3. Available at: http://www.who.int/csr/disease/smallpox/en/bestpractices.pdf.
33. Helle E.P., Koskenvuo K., Heikkila J., Pikkarainen J., and Weckstrom P. Myocardial complications of immunisations. Ann Clin Res 10 (1978) 280-287
34. Karjalainen J., Heikkila J., Nieminen M.S., Jalanko H., Kleemola M., Lapinleimu K., et al. Etiology of mild acute infectious myocarditis. Relation to clinical features. Acta Med Scand 213 (1983) 65-73
35. Cassimatis D.C., Atwood J.E., Engler R.M., Linz P.E., Grabenstein J.D., and Vernalis M.N. Smallpox vaccination and myopericarditis: a clinical review. J Am Coll Cardiol 43 (2004) 1503-1510
36. Kempe C.H. Studies on smallpox and complications of smallpox vaccination. Pediatrics 26 (1960) 600-609
37. Hopkins R.J., and Lane M.J. Clinical efficacy of intramuscular vaccinia immune globulin: a literature review. Clin Infect Dis 39 (2004) 819-826
38. Advisory Committee on Immunization Practices. Record of the February 2003 meeting, Atlanta. Available at: http://www.cdc.gov/nip/ACIP/minutes/acip-min-feb03.pdf.
39. Kempe C., Berge T., and England B. Hyperimmune vaccinal gamma globulin. Source, evaluation, and use in prophylaxis and therapy. Pediatrics 18 (1956) 177-188
40. Hopkins R.J., Kramer W.G., Blackwelder W.C., Ashtekar M., Hague L., Winker-La Roche S.D., et al. Safety and pharmacokinetic evaluation of intravenous vaccinia immune globulin in healthy volunteers. Clin Infect Dis 39 (2004) 759-766
41. Vaccinia Immune Globulin Intravenous (Human) (VIGIV) package insert. Cangene Corporation 2005. Available at: http://www.fda.gov/cber/label/vigivcan050305LB.pdf.
42. Vaccinia Immune Globulin (Human) package insert. Baxter Healthcare Corporation, 1995.
43. Nanning W. Prophylactic effect of antivaccinia gamma-globulin against post-vaccinial encephalitis. Bull World Health Organ 27 (1962) 317-324
44. Data on File. Vaccinia Immune Globulin, Cangene Corporation. March 28, 2005.
45. Vaccinia Immune Globulin Intravenous (Human) (VIGIV) package insert. Dynport Vaccine Company 2005. Available at: http://www.fda.gov/cber/label/vigivdyn021805LB.pdf.
46. 0 (D) Immune Globulin (Human) for injection package insert. Cangene Corporation, 2004.
47. Napolitano P.G., Ryan M.A., and Grabenstein J.D. Pregnancy discovered after smallpox vaccination: is vaccinia immune globulin appropriate?. Am J Obstet Gynecol 191 (2004) 1863-1867